Profile review: 2026-11-06 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
USD IFRS / consolidated
256,691,000
6,793,000 Net income/(loss) attributable to owners of the parent
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: USD thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
Reported parent-attributable earnings differ from total group net income. Adjusted profit is an adjustment to total group net income, not adjusted parent-attributable earnings.
US-headquartered CRO; its annual report identifies Tigermed as the ultimate holding company. Included as a China-controlled listed CRO with explicit cross-border status.
2026H1 · Reporting notes
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: USD thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
Reported parent-attributable earnings differ from total group net income. Adjusted profit is an adjustment to total group net income, not adjusted parent-attributable earnings.
US-headquartered CRO; its annual report identifies Tigermed as the ultimate holding company. Included as a China-controlled listed CRO with explicit cross-border status.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Analytical development, GMP release, bioanalysis and biomarkers
Specialist contract research/testing services
Links Phase I–IIa services to its Secaucus, New Jersey clinic, listing clinical pharmacology, statistics, data management and medical writing.
Headquartered in the United States with operations in China and other regions, providing DMPK, safety assessment, bioanalysis, clinical research, testing, and CMC research/manufacturing.
Listed as HKEX 01521; original 2025 annual and 2026H1 reports reviewed.
Clinical and laboratory platform with China and North America operations, including early-phase clinical services and biometrics. Assess early development fit separately from full-service registrational trial management.
International delivery scope: China-based / China-origin platform
IIT evidence: IIT capability not established by reviewed sources
Program / service
Target / indication
Representative stage
Evidence & scope
Phase I–IIa / clinical pharmacology
Secaucus, NJ clinic; not extrapolated to other group facilities · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
Clinical study data and reporting
Study design, statistical programming, data management and medical writing · Not applicable; population depends on protocol
Services / platform
Clinical research service, not the company’s therapeutic product
Discovery-to-clinical and CMC services
Not applicable (services/platform) · Drug research and manufacturing services for clients
Services / platform
Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Cleveland Clinic reported that the Phase 3 Lp(a)HORIZON trial found no reduction in major cardiovascular events with the antisense drug pelacarsen after median follow-up of 4.7 years. Event rates were 12.3% with pelacarsen and 12.1% with placebo, despite substantial Lp(a) lowering. The findings concern patients with established cardiovascular disease and do not settle outcomes for other Lp(a)-lowering modalities.
European Journal of Drug Metabolism and Pharmacokinetics
A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
Website capabilities are not completed vendor qualification; scope, executing site and current credentials require confirmation.
Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
Consolidated figures overlap with those of the listed controlling parent. The entities may be compared independently but must not be added when estimating industry totals.
Confirm the contracting entity, English-speaking PM, recent international sponsor references and indication-specific site resources.
IIT eligibility, ethics, data access, HGR responsibilities and any intended overseas data use require a project-specific assessment.
